Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia

This study is testing whether interferon-alpha — a medication that boosts immune activity — given after consolidation chemotherapy can help prevent relapse in patients with favorable-risk acute myeloid leukemia (AML) who are in remission but still have tiny amounts of cancer detectable in the blood. **You may be eligible if...** - You are between 18 and 70 years old - You have favorable-risk AML (per 2022 ELN classification) - You achieved complete remission after 1–2 cycles of standard chemotherapy - You completed 4–6 cycles of consolidation chemotherapy - After treatment, a sensitive blood test (MRD) still detects small amounts of leukemia - Your general health is adequate (ECOG 0–2) **You may NOT be eligible if...** - Your AML is in active relapse - You have significant organ dysfunction - You have an active infection or autoimmune disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.